Table 2.

Association between heparin use and clinical outcomes

	Heparin-free group, n (%)	Heparin group, n (%)	OR (95%CI)	P value
Before PSM	n = 421	n = 967
PHLF	66 (15.7)	76 (7.9)	2.180 (1.533, 3.099)	< 0.001
ICU stay	79 (18.8)	129 (13.3)	1.501 (1.104, 2.040)	0.010
Respiratory support	70 (16.6)	72 (7.4)	2.479 (1.745, 3.523)	0.000
CRRT	17 (4)	8 (0.8)	5.044 (2.160, 11.782)	< 0.001
Hypoxemia	39 (9.3)	48 (5.0)	1.955 (1.260, 3.032)	0.003
AKI	40 (9.5)	66 (6.8)	1.433 (0.951, 2.161)	0.086
ICU death	43 (10.2)	43 (4.4)	2.354 (1.543, 3.593)	< 0.001
After PSM	n = 213	n = 213
PHFL	45 (21.1)	28 (13.1)	0.530 (0.303, 0.928)	0.026
ICU stay	49 (23.0)	51 (23.9)	1.722 (0.933, 3.177)	0.082
Respiratory support	43 (20.2)	30 (14.1)	0.502 (0.262, 0.960)	0.037
CRRT	5 (2.3)	4 (1.9)	1.059 (0.249, 4.496)	0.939
Hypoxemia	23 (10.8)	23 (10.8)	1.181 (0.598, 2.334)	0.631
AKI	22 (10.3)	21 (9.9)	1.017 (0.525, 1.971)	0.960
ICU death	27 (12.7)	24 (11.3)	0.956 (0.469, 1.949)	0.901

Bivariate logistic regression analysis with patients before and post propensity score matching was all applied to investigate variables potentially associated with all secondary clinical outcomes. PSM: Propensity score matching; CRRT: Continuous renal replacement therapy; PHFL: Post-hepatectomy liver failure; AKI: Acute kidney injury.